Maximo Agustin Schiavone: What Does ‘Risk-Factor-Free MI’ Really Mean in Practice?
Maximo Agustin Schiavone, Head of Clinical Research – Bariatric and Metabolic Surgery Department at Hospital Universitario Austral, shared a post on LinkedIn about a recent article by Daniel G. Brieger et al, published in Atherosclerosis:
“A ‘risk-factor-free’ heart attack is one of the most uncomfortable truths in preventive cardiology.
Because it exposes a category error we keep making: we treat risk factors as if they were the disease. But the disease is coronary atherosclerosis—and it can be present, active, and dangerous even when the usual checklist looks ‘clean.’
This review puts numbers on it: 14–25% of MI patients present without standard modifiable risk factors (SMuRFs), and SMuRFs explain only ~53–56% of incident CVD events globally. And the inequity signal is loud: SMuRF-less women with MI have nearly a threefold higher early mortality risk compared with men who have at least one risk factor.
So what does ‘risk-factor-free MI’ really mean in practice?
It often means ‘we missed the atherosclerosis’—because our prevention model is built to estimate risk, not to detect disease. The authors explicitly argue for moving beyond probability scores to directly detect the causal disease (atherosclerosis) before symptoms arise.
That framing matters: if you’re ‘SMuRF-less’ the correct clinical reflex shouldn’t be reassurance. It should be better phenotyping and a pathway that stops confusing ‘absence of classic risk factors’ with ‘absence of coronary disease.’
And yes, sex needs to be treated as a biological variable in the whole pipeline, because the performance gaps are most evident in women.”
Title: Coronary artery disease in the absence of standard modifiable risk factors (SMuRFs): The impact of sex
Authors: James Amamoo, Lin Xie, Andrea Steffens, Erin Buysman, Caroline Swift, Sherif Mehanna, Noelle N. Gronroos, Marc P. Bonaca
Read the Full Article on Atherosclerosis
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy